利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.048 秒)

    Multimodal silica-based nanoparticles
    2.
    发明授权
    Multimodal silica-based nanoparticles 有权

    公开(公告)号：US10039847B2

    公开(公告)日：2018-08-07

    申请号：US15714189

    申请日：2017-09-25

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University ,  The Curators of the University of Missouri

    发明人： Michelle S. Bradbury ,  Ulrich Wiesner ,  Oula Penate Medina ,  Andrew Burns ,  Jason S. Lewis ,  Steven M. Larson ,  Thomas P. Quinn

    IPC分类号： A61K51/12 ,  A61K49/00 ,  G01N33/574 ,  G01N33/60 ,  G01N33/58 ,  G01N33/552 ,  G01N33/543

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

    MULTIMODAL SILICA-BASED NANOPARTICLES
    3.
    发明申请
    MULTIMODAL SILICA-BASED NANOPARTICLES 有权

    公开(公告)号：US20180093000A1

    公开(公告)日：2018-04-05

    申请号：US15714189

    申请日：2017-09-25

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University ,  The Curators of the University of Missouri

    发明人： Michelle S. Bradbury ,  Ulrich Wiesner ,  Oula Penate Medina ,  Andrew Burns ,  Jason S. Lewis ,  Steven M. Larson ,  Thomas P. Quinn

    IPC分类号： A61K51/12 ,  A61K49/00 ,  G01N33/574 ,  G01N33/543 ,  G01N33/58 ,  G01N33/552 ,  G01N33/60

    CPC分类号： A61K51/1244 ,  A61K49/0002 ,  A61K49/0093 ,  G01N33/54346 ,  G01N33/552 ,  G01N33/574 ,  G01N33/582 ,  G01N33/587 ,  G01N33/60

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

    Multimodal silica-based nanoparticles
    9.
    发明授权
    Multimodal silica-based nanoparticles 有权

    公开(公告)号：US11419955B2

    公开(公告)日：2022-08-23

    申请号：US16714182

    申请日：2019-12-13

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University

    发明人： Michelle S. Bradbury ,  Ulrich Wiesner ,  Oula Penate Medina ,  Andrew Burns ,  Jason S. Lewis ,  Steven M. Larson

    IPC分类号： A61K51/12 ,  G01N33/574 ,  G01N33/543 ,  G01N33/552 ,  G01N33/58 ,  G01N33/60 ,  A61K49/00

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

    MULTIMODAL SILICA-BASED NANOPARTICLES
    10.
    发明申请
    MULTIMODAL SILICA-BASED NANOPARTICLES 审中-公开

    公开(公告)号：US20200376149A1

    公开(公告)日：2020-12-03

    申请号：US16714182

    申请日：2019-12-13

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University

    发明人： Michelle S. Bradbury ,  Ulrich Wiesner ,  Oula Penate Medina ,  Andrew Burns ,  Jason S. Lewis ,  Steven M. Larson

    IPC分类号： A61K51/12 ,  G01N33/574 ,  G01N33/543 ,  G01N33/552 ,  G01N33/58 ,  G01N33/60 ,  A61K49/00

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.